A Phase 1 Study of HLX20, a Human Monoclonal Antibody Targeting Programmed Death Ligand 1 (PD-L1) Protein in Patients with Advanced Solid Tumors
- Gurney, Howard (Primary Chief Investigator)
- Butala, Radhika, (Other)
- Cunningham, Jacob, (Research Coordinator)
Project: Other › Sponsored clinical trial